Skip directly to site content
Are You Still There?
Due to inactivity, you will be signed out in two minutes unless you click 'Continue'.

Panel:   Aminoglycoside/tetracycline Resistance (ATR)
AR Bank # 0555 Klebsiella pneumoniae
Study ID: ATR-15

Biosample Accession #: SAMN11953987

   
MLST: 437(Pasteur)

MICs obtained by broth microdilution. Modal MIC is reported.

MIC results for each antimicrobial agent for an isolate may commonly be ± 1 log2 (doubling dilution) different than what is posted on the FDA & CDC AR Bank website because this is the normal technical variability of antimicrobial susceptibility testing (see J. H. Jorgensen. 1993. J Clin Microbiol. Vol 31[11]: 2841-2844).

Panel:  Aminoglycoside/tetracycline Resistance (ATR)  |  Cefiderocol Verification (FDC) (Custom)  |  Aminoglycoside/tetracycline Resistance - Gram negative set (ATR-GN) (Custom)


MIC (μg/ml) Results and Interpretation
Drug MIC (μg/ml) INT
Amikacin >64R
Ampicillin >32R
Ampicillin/sulbactam 1>32R
Aztreonam >64R
Cefazolin >8R
Cefepime >32R
Cefepime/zidebactam 50.25---
Cefiderocol 8I
Cefotaxime >64R
Cefotaxime/clavulanic acid 1>32---
Cefoxitin >16R
Ceftazidime >128R
Ceftazidime/avibactam 1>16R
Ceftazidime/clavulanic acid 1>64---
Ceftolozane/tazobactam 1>16R
Ceftriaxone >32R
Ciprofloxacin >8R
Colistin 40.5I
Delafloxacin 2>4R
Doripenem >8R
Eravacycline 20.5S
Ertapenem >8R
Gentamicin >16R
Imipenem 32R
Imipenem/relebactam 132R
Imipenem+chelators 31---
Levofloxacin >8R
Meropenem >8R
Meropenem-vaborbactam 1>16R
Minocycline 16R
Nitrofurantoin >128R
Omadacycline 28I
Piperacillin/tazobactam 1>128R
Plazomicin >128R
Tetracycline 8I
Tigecycline 24I
Tobramycin >16R
Trimethoprim/sulfamethoxazole 1>8R
S – I –R Interpretation (INT) derived from CLSI 2023 M100 S33

1 Reflects MIC of first component
2 Based on FDA break points
3 Screen for metallo-beta-lactamase production [Rasheed et al. Emerging Infectious Diseases. 2013. 19(6):870-878]
4 Clinical and PK/PD data demonstrate colistin has limited clinical efficacy, even if an intermediate result is obtained. Alternative agents are strongly preferred. Colistin should be used in combination with one or more active antimicrobial agents. Consultation with an infectious disease specialist is recommended.
5 Cefepime to zidebactam ratio (1:1)
Device manufacturers and users of FDA cleared devices shall consult the FDA’s Antibacterial Susceptibility Test Interpretive Criteria       website for breakpoints recognized or recommended by FDA, and for information regarding FDA exceptions or additions to the applicable, recognized consensus standard.
Molecular Mechanisms of Resistance
CategoryGene
Aminoglycoside aac(6')-Ib-G, aadA1, aph(3')-Ia, rmtF1
Beta-lactam NDM-5, OXA-232, CTX-M-15, OXA-9, SHV-12, TEM-1A
Bleomycin ble-MBL
Efflux pumps/Other EMRD, KDEA
Macrolide-Lincosamide-Streptogramin mph(A)
Phenicols/Bicyclomycins catB
Quinolone oqxA, oqxB25, QnrS1
Rifampicin ARR-2
Sulfonamides sul1
Trimethoprim dfrA14
 
Disclaimer:
AR gene prediction was performed using ARG-ANNOT and ResFinder databases accessed on 20180608. AR drug classes are assigned according to these databases. This analysis does not include mutations that may result in antibiotic resistance or resistance determinants added to newer versions of used database or other antimicrobial resistance gene databases. For resistance determinant detection, 99-100% sequence identity and 100% sequence coverage from GAMMA and SRST2 was used. GAMMA uses amino acid sequence to assign gene alleles from assemblies; SRST2 uses nucleotide sequence to assign gene alleles from sequencing reads. Biosample accession numbers have been provided so that users can analyze the data on their own if so desired. *MLST Type (and scheme), as determined by Torsten Seemann's MLST program. For Enterobacteriaceae, the Pasteur MLST schemes are used except for E. coli for which both the Pasteur and Achtman schemes are reported. SUB=novel MLST identified and "submitted". **Presence of Efflux Pump may not be associated with resistance.
Propagation
MEDIUM
Medium: Trypticase Soy Agar with 5% Sheep Blood (BAP)

GROWTH CONDITIONS
Temperature: 35°C
Atmosphere: Aerobic

PROPAGATION PROCEDURE

Remove the sample vial to a container with dry ice or a freezer block. Keep vial on ice or block. (Do not let vial content thaw)

Open vial aseptically to avoid contamination

Using a sterile loop, remove a small amount of frozen isolate from the top of the vial

Aseptically transfer the loop to BAP

Use streak plate method to isolate single colonies

Incubate inverted plate at 35°C ± 2°C for 18-24 hrs.

Storage Temperature & Biosafety
STORAGE TEMPERATURE: -70°C

BIOSAFETY LEVEL: 2
Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the current publication of 'BioSafety in Microbiological and Biomedical Laboratories' from the U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, and National Institutes of Health.

Disclaimer:
This product is sent with the condition that you are responsible for its safe storage, handling, and use. All materials are the property of the Centers for Disease Control and Prevention (CDC) and have been made available on behalf of the Food and Drug Administration (FDA). This material is not for use in human subjects and may not be redistributed. While CDC uses reasonable efforts to include accurate and up-to-date information on this product sheet, CDC makes no warranties or representations as to its accuracy. CDC is not liable for damages arising from the misidentification or misrepresentation of cultures. Please refer to the Standard Letter Agreement (SLA) for further details regarding the use of this product.
Isolate History
Date Action Performed
04/20/23INT was updated with a new value for Eravacycline: from 'NS' to 'S'
04/20/23MIC was updated with a new value for Eravacycline: from '1' to '0.5'
11/07/22MLST was updated
10/27/22Category was removed
09/26/22Gene was added
09/26/22Category was added
09/13/22Gene was added
09/13/22Category was added
09/13/22Gene was removed
Top of Page
TOP